Showing 478 news articles about New & experimental hepatitis C treatment

Filters Content type: Editors' picks Topic: New & experimental hepatitis C treatment

News and information about clinical trials and regulatory approval of new medications to treat hepatitis C.

New & experimental hepatitis C treatment

Gilead Provides Update on Hepatitis C Development Programs

Editor's pick
Gilead press release
8 January 2013
New & experimental hepatitis C treatment

Achillion Reports Interim Results on ACH-3102

Editor's pick
Achillion press release
8 January 2013
New & experimental hepatitis C treatment

Medivir announces phase III data for Simeprevir demonstrating efficacy and safety in genotype 1 hepatitis C patients

Editor's pick
Medivir press release
20 December 2012
Hepatitis C treatment side-effects

Vertex hepatitis C drug Incivek gets 'black box' warning over possible fatal skin conditions

Editor's pick
Washington Post
20 December 2012
New & experimental hepatitis C treatment

Hepatitis C - First Interferon-Free Regimens Expected to Launch in 2014 in the United States and Europe

Editor's pick
HCV New Drugs Research
19 December 2012
Pharmaceutical industry

Breaking Up With Gilead Sciences

Editor's pick
The Street
17 December 2012
Pharmaceutical industry

ITPC Open letter from activists in EECA about the Galien Prix Award goint to Merck for boceprevir

Editor's pick
EATG
6 December 2012
Pharmaceutical industry

Copy of ITPC Open letter from activists in EECA about the Galien Prix Award goint to Merck for boceprevir

Editor's pick
GMI Partnership
6 December 2012
New & experimental hepatitis C treatment

Monoclonal antibody GS-6624 well tolerated by patients with hepatic fibrosis in initial safety study

Editor's pick
Healio Hepatology
4 December 2012
New & experimental hepatitis C treatment

Gilead Announces Sustained Virologic Response Rate of 78% From Phase 3 Study of Sofosbuvir for Genotype 2/3 Hepatitis C Infected Patients

Editor's pick
Gilead press release
27 November 2012
New & experimental hepatitis C treatment

New second generation combination therapy for HCV - first or best in the market

Editor's pick
Seeking Alpha
19 November 2012
New & experimental hepatitis C treatment

Copy of New second generation combination therapy for HCV - first or best in the market

Editor's pick
Seeking Alpha
19 November 2012
New & experimental hepatitis C treatment

Gilead may move ahead of rivals with hepatitis C results

Editor's pick
Bloomberg Businessweek
15 November 2012
New & experimental hepatitis C treatment

Copy of Gilead may move ahead of rivals with hepatitis C results

Editor's pick
Bloomberg Businessweek
15 November 2012
New & experimental hepatitis C treatment

Bristol-Myers Squibb’s Investigational Hepatitis C Compounds Lambda and Daclatasvir Plus Ribavirin Achieved SVR12 in 93% of Genotype 1b Treatment-Naive Patients In Phase IIb Study

Editor's pick
HCV New Drugs Research
14 November 2012
New & experimental hepatitis C treatment

Gilead May Top Rivals With Hepatitis C Therapy Results

Editor's pick
Bloomberg BusinessWeek
14 November 2012
New & experimental hepatitis C treatment

Abbott Announces Phase 3 Interferon-free Hepatitis C Regimens to be Studied in Broad Patient Populations

Editor's pick
Abbott press release
14 November 2012
New & experimental hepatitis C treatment

Achillion Provides Update on Clinical HCV Development Programs

Editor's pick
Achillion press release
13 November 2012
New & experimental hepatitis C treatment

Hep C Competitors Cede Space To Gilead And Bristol-Myers And Turn To Niche Uses

Editor's pick
Seeking Alpha
13 November 2012
New & experimental hepatitis C treatment

Gilead Climbs on Study Results of Hepatitis C Combination

Editor's pick
Bloomberg
12 November 2012
New & experimental hepatitis C treatment

Novartis' Certican succeeds in liver transplant trial

Editor's pick
Reuters
12 November 2012
New & experimental hepatitis C treatment

AASLD-GI-5005 Improves Virologic Clearance of HCV in Combination with PegIFN/Ribavirin in IL28B T/T Patients

Editor's pick
HCV New Drugs Research
12 November 2012
New & experimental hepatitis C treatment

Gilead, Abbott Unwrap Dueling Hep C Pill Data

Editor's pick
The Street
12 November 2012
New & experimental hepatitis C treatment

ALS-2200 (VX-135), Vertex's Oral Nucleotide Analogue in Development for Hepatitis C

Editor's pick
Vertex press release
11 November 2012